Navigation Links
Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Date:9/8/2009

SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Conference in New York City. Peter Thompson, M.D., FACP, president, chief executive officer and chairman of the board of directors, and Michelle Burris, senior vice president and chief financial officer, are scheduled to present on Monday, Sept. 14 at 8 a.m. EDT. The presentation will be available via audio webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=2400648.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies dev
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
4. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
5. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
6. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
7. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
10. Trubion Announces Presentations at Upcoming Investor Conferences
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...wswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NB...g letter to its shareholders, discussing the Compa...opharmaceuticals Holdings, Inc. (CHBP), an integra...,s Republic of China. The merger gives NeoStem a c...cal Co. Ltd., CHBP,s primary operating subsidiary ...
(Date:11/19/2009)..., November 19 MONITORING FORCE Gmb... 2009 Flibanserin in the,indication treatment-rele...sease for orphan drug status designation with the ... dyskinesia is a complication of the mainstay,trea... to some of those,affected, since it may be disabl...
(Date:11/19/2009)...Top Gene Synthesis Companies Form International Ge...Practices in Risk Reduction ,Five Member Compani...s Capacity , (PRWEB) Nove... gene synthesis companies today announced agreemen... to promote biosecurity in the gene synthesis indu...
(Date:11/18/2009)...PRNewswire/ -- Marrone Bio Innovations (MBI), a le...zation of effective and environmentally responsibl...been named an IC20 company by the Investors, Circl...angel investing group. ,, Companies named to th...esults for all stakeholders, including investors, ...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Marrone Bio Innovations Named an IC20 Company 2
..., Calif., Oct. 15 The increased emphasis on,safet... costly medical,product development programs and r...ve actions by Sponsors to respond appropriately. E...d in consulting organizations. GZP,has already emp...ce errors,that can lead to adverse regulatory acti...
...IN VIEW, Calif., Oct. 14 Based on its recent,anal...recognizes ISTO,Technologies, Inc. with the 2008 N...nnovation for its novel InQu(R) Bone Graft Extende...st commercial product launched by the,company usin...ology., Although spinal fusions and other orthope...
...D, Mass., Oct. 14 John Santini, Jr., PhD, CEO of,...zine as a member of the,2008 class of "young geniu... of this annual list, Dr. Santini is the only hono...eneur running his own commercial venture.,His comp... devices for drug,delivery and biochemical sensing...
Other Biology Technology:Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 3Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 2Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 3Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 4MicroCHIPS CEO Named in Popular Science's 'Seventh Annual Brilliant 10' 2
(Date:11/23/2009)...iscoveries about the multiple health benefits of v...e nutrient, increased awareness of the huge number...rch and even led to an appreciation of it as "natu...ealth of your immune system to prevention of heart...min D is now seen as one of the most critical nutr...
(Date:11/23/2009)... , , , , , , , ...Andrew Marshall, from the Environment Department a...of Kinyongia magomberae and his wider work in Ta...nformation. , , , , , ... , , , , , A new species of chameleon ...
(Date:11/23/2009)...er of six-week-old turkey poults could save millio...birth, according to Dr. Gerald Steiner from the Dr...team. Their use of infrared spectroscopy to determ...ast and accurate method with the potential to be u...t female eggs for breeding. The pilot study has ju...
Breaking Biology News(10 mins):Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Rescuing male turkey chicks 2Providence Service Corporation Comments on U S Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10 25 Cut in Medi Cal Paym 51766 1Providence Service Corporation Comments on U S Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10 25 Cut in Medi Cal Paym 51766 2Providence Service Corporation Comments on U S Court of Appeals Decision to Uphold Federal Injunction Blocking Californias 10 25 Cut in Medi Cal Paym 51766 3EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP 6124 Phase Ib IIa Trial at the International Conference on Alzheimers Diseas 13042 1EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP 6124 Phase Ib IIa Trial at the International Conference on Alzheimers Diseas 13042 2Rare Cells Linked to Pediatric Cancers 51764 1Rare Cells Linked to Pediatric Cancers 51764 2
...a consequence of their inability to adapt to new e...tion with other species. Besides selection and the...ptation is also one of the driving forces behind e... been familiar since Darwin, these processes incre...f two competing species, only the fittest would su...
...irds of all patients with dementia suffer from Alz...our country will have more than 150,000 Alzheimer,...y destroys brain cells, with the result that the m...lly declines. At first, memory begins to fail, but...rate as the disease progresses. Today, this diseas...
... German . , , Plants, algae, and cyanobacteria ... with solar energy because they are able to almost...cal energy. This is in part because the electrons ... "light receptor" 1:1 to be used as the driving fo...ave now developed a new process to capture light e...
Other Biology News:The law of the weakest 2The law of the weakest 3New target for medicine to combat Alzheimer's: VIB scientists confirm protein's key role 2Plugging in molecular wires 2
Prostaglandin D2 , 5,6,8,9,12,14,15(n)-3H Conjugated/Tagged from GE Healthcare, formerly Amersham Biosciences
QuantiChrom™ Sulfate Assay Kit from BioAssay Systems
Mouse Serum from Lifeblood Medical, Inc.
Mouse Serum from Innovative Research
Biology Products: